||
破解EGFR突变NSCLC一线靶向治疗耐药难题
https://mp.weixin.qq.com/s/DSjdHeWoOB4OifwACd5Gaw
INSIGHT 2研究不仅为EGFR突变NSCLC患者提供了一种新的治疗策略,也为未来的临床研究和实践指明了方向,特别是在MET扩增的检测、联合治疗的优化以及个体化治疗的进一步探索方面。
http://www.pubmedplus.cn/P/SearchQuickResult?wd=9f95577d-3cd5-4841-a585-22f6306e2905
01. | Humans | 20 篇 | 64.516% |
02. | Carcinoma, Non-Small-Cell Lung | 19 篇 | 61.290% |
03. | Lung Neoplasms | 19 篇 | 61.290% |
04. | ErbB Receptors | 18 篇 | 58.065% |
05. | Male | 13 篇 | 41.935% |
06. | Female | 11 篇 | 35.484% |
07. | Mutation | 11 篇 | 35.484% |
08. | Aged | 9 篇 | 29.032% |
09. | Protein Kinase Inhibitors | 8 篇 | 25.806% |
10. | Antineoplastic Agents | 7 篇 | 22.581% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-8-15 10:13
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社